IBD Research Resource Center

Clinical ID	c2377
Identifier	ACTRN12621001098820
Trial Title	Modulating Cardiovascular Risk in Inflammatory Bowel Disease Patients.
Trial URL	Visit Original Page

Study Results	No results available
Conditions	Crohn's Disease;Cardiovascular Disease;Irritable Bowel Syndrome;Ulcerative Colitis; Crohn's Disease Cardiovascular Disease Irritable Bowel Syndrome Ulcerative Colitis;Oral and Gastrointestinal - Crohn's disease;Cardiovascular - Other cardiovascular diseases;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions	This study is observing the cardiovascular disease regression in patients who are at risk of cardiovascular disease and are requiring treatment for their Crohn's Disease or the Ulcerative Colitis. All patients will be provided the standard Crohn's Disease or Ulcerative Colitis biologic therapy that is available on the pharmacutical benefits scheme (PBS) if they meet the criteria outlined by the PBS. This therapy could be either Adalimumab or Infliximab at their standard dosing regieme. Patients will attend their regular clinic appointments, which the protocol was designed to accommodate. Clinic appointments will occur at baseline, at week 12 and at week 24. The clinic appointments will take approximately 20 to 30 minutes each. The Computer Tomography Coronary Angiogram (CCTA) scan will occur on a separate visit and will take 1 hour in total on both the baseline and week 24 visit.

Sex Requirement	ALL
Age Requirement	ADULT, ELDER, OLDER_ADULT

Study Type	Observational
Phase	Not Available